Neuromodulation of the cervical sympathetic chain to treat cortical spreading depression
Neuromodulation of the cervical sympathetic chain, particularly at the superior cervical ganglion, addresses the challenge of preventing migraine pain by stabilizing cerebral blood flow and mitigating cortical spreading depression through targeted stimulation, effectively reducing the onset of migraine symptoms.
Patent Information
- Application Number
- PCT/EP2026/064211
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
Migraines, characterized by cortical spreading depression, present clinical challenges due to their debilitating nature and the difficulty in effectively preventing or mitigating symptoms before they worsen.
Neuromodulation of the cervical sympathetic chain, specifically targeting the superior cervical ganglion, is employed to stabilize cerebral blood flow and prevent the onset of migraine pain by using implantable electrodes and stimulators that deliver focused ultrasound, electrical, or chemical stimulation in response to prodromal symptoms.
This approach prevents migraine pain by mitigating cerebral vasoconstriction and reactive vasodilation, increasing metabolic waste clearance, and stabilizing cranial blood flow, thereby reducing the activation of pain pathways associated with cortical spreading depression.
Smart Images

Figure EP2026064211_19112026_PF_FP_ABST
Abstract
Description
WIPRef: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaNEUROMODULATION OF THE CERVICAL SYMPATHETIC CHAIN TO TREAT CORTICAL SPREADING DEPRESSIONINCORPORATION BY REFERENCE TO ANY PRIORITY APPLICATIONS
[0001] This application claims priority benefit of U.S. Provisional Application No. 63 / 806,168 filed May 15, 2025, which is hereby incorporated by reference in its entirety herein.FIELD
[0002] The present disclosure relates generally to systems and methods forfacilitating modulation, and more particularly in some embodiments to systems and methods forfacilitating therapeutic modulation of the nerves around a subject’s cervical sympathetic chain for the purpose of treating cortical spreading depression.BACKGROUND
[0003] Migraines are debilitating neurological disorders characterized by recurrent, intense headaches typically accompanied by a myriad of symptoms such as nausea, vomiting, and sensitivity to light and sound. These episodes, often lasting for hours to days, significantly disrupt daily life and productivity for millions worldwide. Various factors contribute to their onset, including genetic predispositions, environmental triggers, and alterations in brain chemistry and structure. Neurostimulation approaches have been attempted to treat migraines.SUMMARY
[0004] The multifaceted nature of migraines presents clinical challenges, highlighting the necessity for comprehensive approaches aimed at improving diagnosis, treatment, and quality of life for those affected. Although treatment of a full-blown migraine is beneficial, several embodiments described herein prevent or mitigate migraine before it begins or worsens by treating cortical spreading depression.
[0005] Migraine pain can occur in discrete episodes with symptom-free intervals between episodes. The pain can be moderate to severe, throbbing or pulsatile, and often localized to one side of the head, especially the frontotemporal or periorbital region. It usually builds gradually over 1-2 hours, rather than reaching peak intensity immediately, and may last 4 to 72 hours if untreated. Provided herein, in several embodiments, are systems and methods to treat cortical spreading depression to prevent activation of pain pathways causing migraines and other disorders where cortical spreading depression plays a role in undesired symptoms (e.g., headache disorders, facial pain, sensory numbness, etc.).WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tba
[0006] In several embodiments, systems and methods are provided for neuromodulation of the cervical sympathetic chain to improve cerebral blood flow and treat cortical spreading depression in a subject. T reatment of cortical spreading depression can occur prior to the onset of migraine pain to prevent head pain from occurring. Rather than treat the migraine pain, the systems described herein pre-empt the migraine pain from occurring. The system described herein includes a neuromodulation element (e.g., at least one electrode) and a stimulator in communication with the neuromodulation element. In some embodiments, the neuromodulation element can include an ultrasound element, a chemical element, and / or a light-based element. An ultrasound element can include 5 to 20 crystals to provide focused ultrasound. The neuromodulation element can be positioned (e.g., implanted) at or near the cervical sympathetic chain to modulate (e.g., stimulate) the cervical sympathetic chain. Some embodiments herein are directed toward modulating only the superior cervical ganglion (SCG) of the cervical sympathetic chain without directly modulating the middle cervical ganglion, the inferior cervical ganglion, or postganglionic branches of the SCG. Some embodiments herein are directed toward modulating a region between the SCG and the middle cervical ganglion, referred to as the cervical sympathetic chain (CSC) or cervical sympathetic trunk (CST). In some embodiments, stimulation may be delivered to only the SCG and / or at least a portion of the MCG without stimulating the inferior cervical ganglia, one or more postganglionic branch connections of the SCG, the vagus nerve, and / or the sphenopalatine ganglion. Neuromodulation of the cervical sympathetic chain can increase, decrease, and / or stabilize cranial blood flow by mitigating cerebral vasoconstriction and reactive vasodilation associated with cortical spreading depression. Neuromodulation of the cervical sympathetic chain may additionally cause an increase in clearance of metabolic waste, the glymphatic system, and / or meningeal lymphatic vessels. Neuromodulation of the cervical sympathetic chain may additionally mitigate and / or prevent trigeminal autonomic reflexes.
[0007] Neuromodulation can be delivered in response to a user input. For example, when a subject begins to experience a prodrome indicating the onset of cephalalgia (e.g., aura such as temporary visual disturbances, increased secretions of saliva, and / or increased urination), a user (e.g., the subject and / or a clinician) can activate the stimulator to deliver stimulation to the target site. The stimulator can send a signal to the neuromodulation element in response to the user input. The stimulator may be external to the subject (e.g., in the form of a remote and / or wearable device). In some embodiments, the stimulator may be implanted in the subject (e.g., anchored to the sternocleidomastoid muscle or tendon). In some embodiments, the therapy may be initiated, stopped, and / or adjusted by the subject, for example from a remote device, such as a mobile phone, a tablet, patient controller, computer, patch, wearable, or otherwise.
[0008] The system may additionally include one or more monitoring devices. In some embodiments, the one or more monitoring devices may be used to track and detect changes in the cerebral effects of the stimulation in real-time. In some embodiments, the one or more monitoring devices may be used to detect a prodrome indicating onset of a migraine. The one or more monitoring devices can monitor changes in one orWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbamore physical biomarkers such as, for example, blood flow, pupil diameter, saliva generation, skin perspiration, etc. In some embodiments, the stimulator can send a signal to the electrode to electrically stimulate the cervical sympathetic chain in response to the monitoring device detecting the change in the biomarker associated with a prodrome.
[0009] Neuromodulation may be delivered to the cervical sympathetic chain for a duration of less than or equal to 60 minutes, for example 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 60 minutes, time periods less than such values, between such values, and the like. Stimulation may be delivered for a portion of the duration of experienced aura (e.g., 50% of the duration of aura, 100% of the duration of aura). The stimulation may be performed at a current of between approximately 1 milliampere (mA) and approximately 10 mA, for example approximately 1 mA, 2 mA, 3 mA, 4 mA, 5 mA, 6 mA, 7 mA, 8 mA, 9 mA, 10 mA, ranges between such values, and the like. The stimulation may be applied at a frequency of between 1 Hz and 20 Hz, for example approximately 1 Hz, 2 Hz, 5 Hz, 10 Hz, 15 Hz, 20 Hz, less than such values, ranges between such values, and the like. The stimulation may be applied with a pulse width of between approximately 50 microseconds (pis) and approximately 2 milliseconds (ms), for example approximately 50 pis, 500 pis, 600 pis, 700 pis, 800 pis, 900 pis, 1000 pis, 1 ms, 1.5 ms, 1.9 ms, ranges between such values, and the like. As one example, stimulation may be delivered at a frequency of less than or equal to 10 Hz and for a duration between 5 and 60 minutes (e.g., between 5 minutes and 30 minutes).
[0010] The present disclosure also relates to a method for treating cortical spreading depression in a subject using stimulation of the cervical sympathetic chain in several embodiments. The method may include positioning an implantable electrode in electrical communication with a cervical sympathetic chain of the subject. The electrode may be positioned by percutaneously inserting a needle and / or catheter into a target site of the cervical sympathetic chain. In some embodiments, the electrode may be implanted at or proximate to the SCG of the subject, and not placed on the skin surface for transcutaneous stimulation. In some embodiments, the electrode may be implanted at a region of the cervical sympathetic chain between the middle cervical ganglion and the superior cervical ganglion of the subject. In response to the subject experiencing a prodrome indicating onset of cephalalgia, a user may activate a stimulator to send a signal to the electrode to electrically stimulate the cervical sympathetic chain at the target site. The stimulator may be a remote device operated by the subject or a clinician. Stimulation can stabilize cerebral vasculature by inhibiting (e.g., preventing) reflex vasoconstriction to counteract and / or prevent cortical spreading depression. Stimulation of the cervical sympathetic chain can additionally cause an increase in clearance of metabolic waste within cerebral blood flow. Treatment of cortical spreading depression can occur before the onset of head pain to prevent head pain from occurring.
[0011] In some embodiments, the neuromodulation (e.g., neurostimulation) parameters described herein reduce the amount of neurotransmitters being released during the onset activation of pain associated with migraine. CSD causes a release of neurotransmitter in and around the trigeminal afferents nerves that run alongWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbathe surface of the cerebral vascular. When CSC occurs the neurotransmitter released cause direct activation of trigeminal afferents. When stimulating the CSC, during CSD, the stimulation will stabilize the cerebral vasculature and reduce the amount of neurotransmitters being released as part of the CSD event, which in turn will reduce the amount activation of trigeminal afferents and reduce or eliminate the onset activation of the trigerminal-autonomic reflex, which ultimately will reduce or eliminate the pain associated with the aura event. In addition to being helpful for migraines, the therapies provided herein may also help other neurological disorders where global cerebral or regional cerebral blood flow needs to be regulated and aid with treatment or recovery (e.g., stroke patients and those with traumatic brain injuries, vasospasm post stroke, hemorrhage, and other similar impairments by treating ion imbalances and / or depolarization). Hemisphere to hemisphere changes in CBF have been linked to preictal prediction of onset of seizures. Accordingly, stimulation of the CSC to cause stabilization of blood flow across cortical hemispheres can also inhibit epilepsy.
[0012] The technology provided herein, according to several embodiments, provides innovative solutions that use both neuromodulation and artificial intelligence to help users suffering from migraine and other disorders involving cortical spreading depression. Using machine learning and Al, several embodiments provided herein automatically adjust stimulation parameters to provide personalized therapy, which can be optimized continuously to benefit the user.
[0013] In several embodiments, the stimulation of nerves and / or other tissue described herein work synergistically with other therapies, such as pharmacological therapies (e.g., drugs such as beta-blockers, triptans, botulinum, NSAIDs, topiramate, antidepressants, or CGRP-targeted drugs), for example by reducing the frequency, dose, side effects, etc. of these other therapies. In other embodiments, the technologies described herein are able to replace these other therapies.
[0014] In several embodiments, the systems and methods described herein have one or more of the following advantages:• prevent head pain associated with migraines;• improve symptoms associated with migraine with aura;• inhibit or prevent cortical spreading depression;• improve and / or regulate / stabilize cerebral vascular flow of a subject;• activate neuromodulation in response to a user input;• activate neuromodulation in response to a detected prodrome indicating onset of a migraine;• be minimally invasive; and• allow for at-home treatment.
[0015] In several embodiments, open loop, closed loop, or both open and closed loop feedback is provided. For example, a user may advantageously select a particular stimulation setting based on certain lifestyle-I-WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaevents. A user may choose increased stimulation based on stress, irregular or poor sleep, hormones (e.g., changes in estrogen and progesterone during a menstrual cycle), specific foods (e.g., chocolate), caffeine, alcohol (e.g., tannins in wine), light, specific smells, dehydration, medications, among others.
[0016] In some embodiments, a system may include an implantable electrode configured to be positioned in electrical communication with the cervical sympathetic chain of the subject, a stimulator configured to send a stimulation signal to the implantable electrode to electrically stimulate the cervical sympathetic chain, and a processor. The processor can be configured to receive an input from the subject, and in response to receiving the input from the subject, send instructions to the stimulator to send the stimulation signal to the implantable electrode. The implantable electrode, upon receiving the stimulation signal, stimulates the cervical sympathetic chain to reduce cortical spreading depression.
[0017] In some embodiments, the stimulation signal includes a frequency of less than or equal to 10 Hz (e.g., 1 Hz, 2 Hz, 5 Hz, 7 Hz). The stimulation signal can include a duration between 5 minutes and 60 minutes (e.g., 10 minutes, 30 minutes, 45 minutes). In some embodiments, the stimulator can include an implantable anchor configured to be anchored to a muscle of the subject (e.g., an SCM muscle). The implantable electrode may be configured to be positioned in electrical communication with a superior cervical ganglion.
[0018] In some embodiments, a system includes an implantable electrode configured to be positioned in electrical communication with the cervical sympathetic chain of the subject, a stimulator configured to send a stimulation signal to the implantable electrode to electrically stimulate the cervical sympathetic chain, and a processor. The stimulator can include an anchor configured to be anchored to a sternocleidomastoid muscle or tendon of the subject. The processor can be configured to receive an input from a user, and in response to receiving the input from the user, send instructions to the stimulator to send the stimulation signal to the implantable electrode. The stimulation signal includes a frequency of less than or equal to 20 Hz (or less than or equal to 10 Hz, or less than or equal to 5 Hz) at a duration of at least 5 minutes and / or less than or equal to 60 minutes (or less than or equal to 30 minutes, less than or equal to 15 minutes).
[0019] In some embodiments, the system further includes a second implantable electrode configured to be positioned in electrical communication with a middle cervical ganglion. Optionally, the system may include a monitoring device (e.g., sensor or imaging device) configured to monitor one or more biomarkers of the subject. The stimulator can be configured to send the stimulation signal to the implantable electrode based on the one or more biomarkers detected or changes in biomarkers. The one or more biomarkers can include one or more of cranial blood flow, pupil size, and saliva generation. The monitoring device can includes an imaging modality (e.g., near infrared spectroscopy (NIRS)) configured to monitor one or more cranial biomarkers of the subject. A frequency and / or a duration of the stimulation signal may be determined using artificial intelligence.
[0020] In some embodiments, the electrical stimulation of the cervical sympathetic chain can cause an increase in clearance of one or more of metabolic waste, a glymphatic system of the subject, and meningealWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbalymphatic vessels of a subject. The electrical stimulation of the cervical sympathetic chain may cause cerebral vasodilation to mitigate the cortical spreading depression prior to onset of pain associated with the cortical spreading depression. In some embodiments, the implantable electrode is configured to be positioned to stimulate the cervical sympathetic chain without stimulating a sphenopalatine ganglion, spinal cord, or a vagus nerve.
[0021] In some embodiments, a method for treating cortical spreading depression in a subject includes positioning an implantable electrode in electrical communication with a cervical sympathetic chain of the subject. In response to the subject experiencing a prodrome indicating onset of cephalalgia, a stimulation signal can be sent via a stimulator to the implantable electrode to electrically stimulate the cervical sympathetic chain. Electrical stimulation of the cervical sympathetic chain via the implantable electrode can cause cerebral vasodilation to mitigate cortical spreading depression prior to onset of cephalalgia associated with cortical spreading depression.
[0022] In some embodiments, a method for treating cortical spreading depression in a subject includes positioning an implantable electrode in electrical communication with a cervical sympathetic chain of the subject. In response to the subject experiencing aura indicating onset of a migraine with aura, a stimulation signal can be sent via a stimulator (e.g., automatically or based on user input) to the implantable electrode to electrically stimulate the cervical sympathetic chain. Electrical stimulation of the cervical sympathetic chain via the implantable electrode can cause stabilized cerebral blood flow to mitigate cortical spreading depression without treating pain associated with the migraine.
[0023] In some embodiments, a method for treating cortical spreading depression in a subject includes positioning an implantable electrode in electrical communication with a superior cervical ganglion of the subject. In response to the subject experiencing aura indicating onset of a migraine with aura, a stimulation signal can be sent via a stimulator to the implantable electrode to electrically stimulate the superior cervical ganglion. Electrical stimulation of the superior cervical ganglion via the implantable electrode can stabilize cerebral blood flow. Stabilizing cerebral blood flow mitigates direct and indirect activation of a trigeminal afferents and subsequent activation of the trigeminal-autonomic reflex to prevent onset of head pain.
[0024] The prodrome or aura can include visual disturbances, increased secretions of saliva, and / or increased urge to urinate, among many others. In some embodiments, the electrical stimulation can be delivered at a frequency of less than or equal to 10 Hz (e.g., 1 Hz, 2 Hz, 5 Hz, 7 Hz, or other values and ranges provided herein). The electrical stimulation may be delivered for a duration of at least about 5 minutes and / or less than or equal to 60 minutes (e.g., less than or equal to 10 minutes, less than or equal to 30 minutes, or less than or equal to 45 minutes). In some embodiments, the electrical stimulation of the cervical sympathetic chain causes an increase in clearance of one or more of metabolic waste, a glymphatic system of the subject, and meningeal lymphatic vessels of a subject. The stimulator can be anchored to a sternocleidomastoid muscle of the subject.WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaThe implantable electrode may be positioned to stimulate the cervical sympathetic chain without stimulating a spinal cord, vagus nerve, or sphenopalatine ganglion.
[0025] In some embodiments, a system can electrically stimulate a cervical sympathetic chain in a subject to prophylactically treat cephalalgia. The system can include an implantable electrode configured to be delivered into electrical communication with the cervical sympathetic chain. The system can additionally include a monitoring device (e.g., sensor or imaging device) configured to detect a change in a biomarker of the subject associated with a prodrome indicating onset of cephalalgia. The system can also include a stimulator configured to send a signal to the implantable electrode to electrically stimulate the cervical sympathetic chain in response to the monitoring device detecting the change in the biomarker. In some embodiments, the biomarker includes skin perspiration and / or saliva generation. The stimulator can be wearable (e.g., a skin patch).
[0026] In some embodiments, a method for modulating cranial blood flow in a subject includes positioning an implantable electrode in electrical communication with a cervical sympathetic chain of the subject. An external stimulator can be activated to send a signal to the implantable electrode. The cervical sympathetic chain can be electrically stimulated via the implantable electrode in response to the signal. The stimulation can be applied to treat symptoms of migraine with aura. The stimulation may be initiated by the subject in response to a prodrome (e.g., temporary visual disturbances, increased secretions of saliva, and / or increased urination). Electrically stimulating the cervical sympathetic chain can increase, decrease, and / or or stabilizes cranial blood flow. The stimulation can cause increases in clearance of metabolic waste, a glymphatic system of the subject, and / or meningeal lymphatic vessels.
[0027] In some embodiments, activating the external stimulator includes the subject inputting an instruction on a wearable device. The method may further including locating a target site on the cervical sympathetic chain of the subject for positioning the implantable electrode. The target site may be located at or proximate to a superior cervical ganglion of the subject. The target site may be located at a region of the cervical sympathetic chain between a middle cervical ganglion and a superior cervical ganglion of the subject.
[0028] In some embodiments, a method for electrically stimulating a cervical sympathetic chain in a subject includes positioning an electrode in electrical communication with a cervical sympathetic chain of the subject. A stimulator can be activated to send a signal to the electrode in response to a clinician input to send the signal to the electrode to electrically stimulate the cervical sympathetic chain. The cervical sympathetic chain can be electrically stimulated via the electrode. The electrode can be percutaneously positioned by inserting a needle into a target site of the cervical sympathetic chain. The electrode may be disposed on a distal tip of the needle. In some embodiments, the target site can be located at or near a superior cervical ganglion of the subject. The target site may be located at a region of the cervical sympathetic chain between a middle cervical ganglion and asuperior cervical ganglion of the subject.WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tba
[0029] Electrically stimulating the cervical sympathetic chain can stabilize cranial blood flow. Electrically stimulating the cervical sympathetic chain can also increase clearance of metabolic waste, a glymphatic system of the subject, and / or meningeal lymphatic vessels of a subject. The clinician input may be made in response to an observed change in cranial blood flow.
[0030] In some embodiments, a method of modulating cranial blood flow in a subject includes locating a target stimulation site on a cervical sympathetic chain of the subject. An electrode can be positioned at the target stimulation site. A stimulator can be activated to send a signal to the electrode. The method can also include detecting a change in a physiological parameterorcondition of the subject. The cervical sympathetic chain can be electrically stimulated via the electrode based on the detected physiological parameter or condition. In some embodiments, a change in cranial blood flow or skin sympathetic nerve activity may be detected. Near infrared spectroscopy (NIRS) may be used to detect the change in the physiological parameterorcondition. NIRS can be used to sense cortical or superficial blood flow. Sympathetic nervous system activity can be sensed through skin impedance measurements, among other techniques.
[0031] In some embodiments, positioning the electrode at the target stimulation site includes percutaneously introducing a needle into vasculature of the subject with the electrode located at a distal tip of the needle. Specifically, the needle may be positioned in a posterior groove of longus capitis and longus colli muscle groups near a transverse process of a vertebra of the subject. The target stimulation site can be located at or near a superior cervical ganglion of a subject. In some embodiments, the target stimulation site is between a middle cervical ganglion and a superior cervical ganglion of the subject. The target stimulation site can be located via ultrasound imaging. When using an ultrasound technique, the electrode can be introduced medially or laterally. Because the CSC sits on the longus coili muscle, lateral placement may advantageously avoid any injury to the carotid. In some embodiments, the electrode may be intravascularly placed (e.g., through the internal carotid artery) for intravascular stimulation.
[0032] Any system or method described herein may be used for the prevention and / or treatment of one or more of migraine, headache disorders, stroke, and brain injury. Any system or method described herein may be used for the treatment of cortical spreading depression without treating pain associated with a migraine. Any system or method described herein may be used for the stimulation of the cervical sympathetic chain without stimulating the spinal cord, lumbar sympathetic chain, inferior cervical ganglia, postganglionic branches or connections of the SCG, the vagus nerve, and / or the sphenopalatine ganglion, artificial intelligence and / or machine learning can be used to optimize stimulation patterns. Any system or method described herein may be provide synergistic combination therapies with drugs and other interventions. Additionally, any system or method described herein may be used open-loop feedback, closed-loop-feedback, or both, and neurostimulation parameters are provided and / or adjusted based on such feedback.WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaBRIEF DESCRIPTION OF THE DRAWINGS
[0033] The following drawings are for illustrative purposes only and show non-limiting embodiments. Features from different figures may be combined in several embodiments.
[0034] FIG. 1 is a schematic drawing of the cervical sympathetic chain in the right cervical region of the human anatomy.
[0035] FIG. 2 is a schematic diagram of an example at-home system for modulating nerves.
[0036] FIG. 3 is a flowchart of an example method of treating a subject for migraines using the example system of Figure 2.
[0037] FIG. 4 is a schematic diagram of another example at-home system for modulating nerves.
[0038] FIG. 5 is a flowchart of an example method of treating a subject for migraines using the example system of Figure 4.
[0039] FIG. 6 is a schematic diagram of an example clinical system for modulating nerves.
[0040] FIG. 7 is a schematic diagram of another example clinical system for modulating nerves.
[0041] FIG. 8 is a flowchart of an example method of treating a subject for migraines using the example clinical systems of either Figure 6 or Figure 7.
[0042] FIG. 9 is a schematic diagram of an example system for modulating nerves that is fully external to a subject.
[0043] FIG. 10 is a flowchart of an example method of treating a subject for migraines using the example system of Figure 9.DETAILED DESCRIPTION
[0044] Several embodiments described herein prevent or mitigate migraine before it begins or worsens by treating cortical spreading depression. Other disorders and symptoms that involve treating cortical spreading depression are also treated according to several embodiments. In addition to mitigating migraines, the therapies provided herein may also be used to treat other neurological disorders where global cerebral or regional cerebral blood flow needs to be regulated and aid with treatment or recovery (e.g., stroke patients and those with traumatic brain injuries, vasospasm post stroke, hemorrhage, epilepsy, and other similar impairments).
[0045] In several embodiments, migraine is treated. There are a variety of sub-types of migraines, a common one being migraine with aura (MwA). Auras are symptoms that can occur prior to head pain beginning, and can include, for example, temporary visual disturbances, increased secretions of saliva, increased urination, increased urge to urinate, or other disturbances. Aura can indicate the onset of head pain. In some instances, a subject (e.g., an individual) may not experience head pain until 4 to 8 hours after initially experiencing aura. It has been found that cortical spreading depression (CSD) may be the pathophysiological correlate of the neurological symptoms in migraine aura. CSD is an intense self-propagating wave of depolarization involving neuronal and glial cells in the cerebral cortex, subcortical gray matter, or retina, irrespective of functional divisions or arterialWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaterritories. This depolarization is followed by a longer lasting wave of inhibition characterized by massive changes in ionic concentrations and slow chemical waves, propagating at a rate of approximately 3-6 mm / min. CSD affects cerebral blood flow by causing an initial cerebral vasoconstriction followed by a reactive cerebral vasodilation and tissue hyper-oxygenation which are responsible for head pain. CSD can start anteriorly (e.g., behind the eyes) then spread posteriorly to the back of the head. Propagation of the CSD wave may occur within 3 to 5 minutes. The vasoconstriction and reactive vasodilation of cerebral blood vessels can activate trigeminal nerves which causes a release of neurotransmitters (e.g., calcitonin gene-related peptide, nitric oxide, acetylcholine), resulting in neurogenic inflammation. This trigeminal autonomic reflex may result in the initiation of migraine pain. The systems described herein may be particularly beneficial for subjects with MwA.
[0046] The onset of a migraine (and / or the associated aura) may be caused by one or more triggers. Triggers can include stress, irregular or poor sleep, hormones (e.g., changes in estrogen and progesterone during a menstrual cycle), specific foods (e.g., chocolate), caffeine, alcohol (e.g., tannins in wine), light, specific smells, dehydration, medications, among others. The triggers causing a migraine can vary from person to person.
[0047] A therapy involving innate activation of specific neural circuits in combination with regulating and / or stabilizing cerebral blood flow may induce specific neural and therapeutic responses in subjects suffering from migraines that alleviate or prevent symptoms from occurring. Cephalalgia, also referred to as headache, can include any pain in the head, face, and / or neck. Cephalalgia can include migraines and autonomic cephalalgias. It is to be understood that any references made to regulating and / or stabilizing cerebral blood flow refers to increasing both blood flow into the brain (i.e., arterial flow) and blood flow out of the brain (i.e. , venous flow).
[0048] The cervical sympathetic chain (CSC) is part of the sympathetic division of the autonomic nervous system, which is responsible for maintaining homeostasis of the body. The sympathetic nervous system is composed of pathways that lead to and from groups of nerve cells known as ganglia. A ganglion allows a large amount of divergence in a neuronal pathway and also enables a more localized circuitry for control of the innervated targets. The CSC comprises of the intercommunicating nerve segment that connects three main ganglia: the superior cervical ganglion (“SCG”), the middle cervical ganglion (“MCG”), and the inferior cervical ganglion (“ICG”). The SCG is the only ganglion in the sympathetic nervous system that innervates the head and neck. It is the largest and most rostral (superior) of the three cervical ganglia. The SCG innervates many organs, glands, and parts of the carotid system in the head. It is formed by the coalescence of four ganglia, corresponding to the upper four cervical nerves, C1-C4. The bodies of these preganglionic sympathetic neurons are specifically located in the lateral horn of the spinal cord. These preganglionic neurons then enter the SCG and synapse with the postganglionic neurons that leave the rostral end of the SCG and innervate target organs of the head.
[0049] There may be several target stimulation sites in the CSC that allow for neural circuit activation and modulation of cerebrovascular flow in a subject for the purpose of treating migraine symptoms. TheWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaSCG may be an ideal stimulation target in one embodiment. Stimulation of the SCG can refer to stimulation of the SCG without direct stimulation of the spinal cord, middle cervical ganglia, inferior cervical ganglia, one or more postganglionic branch connections of the SCG, the lumbar sympathetic chain, the vagus nerve, and / or the sphenopalatine ganglion. Accordingly, in some embodiments, a neuromodulation element can be positioned adjacent to the SCG to directly stimulate the SCG without directly stimulating the middle cervical ganglia, inferior cervical ganglia, postganglionic branches or connections of the SCG, and / or the sphenopalatine ganglion. Stimulation of the SCG may result in indirect stimulation of the middle cervical ganglia, the inferior cervical ganglia, and / or the postganglionic branches, and / or the sphenopalatine ganglion. In other embodiments, postganglionic branches or connections thereof of the SCG may be directly stimulated by positioning one or more neuromodulation elements adjacent to the target postganglionic branch connection. In some embodiments, stimulation may be delivered to the SCG and / or at least a portion of the MCG without stimulating the inferior cervical ganglia, one or more postganglionic branch connections of the SCG, the vagus nerve, and / or the sphenopalatine ganglion. Stimulation of the conductive tissue surrounding the SCG may lead to vasodilation within the subject’s head, face, neck, and upper extremities, resulting in improved blood flow. The portion of the CSC between the MCG and SCG may also be a suitable stimulation target site for increasing blood flow to the brain and may be more easily accessed than the SCG itself. The interconnecting fibers between the MCG and the ICG and the vagus nerve may also be a desired stimulation target as it could induce a sympathetic response while acting as a parasympathetic blocker (e.g., stimulating these fibers very quickly could result in a strong sympathetic response without creating a parasympathetic reflex). The SCG advantageously provides innervation to the entirety of the head and such that stimulation of the SCG can improve vertebral artery blood flow and cause widespread cerebral vasodilation. In contrast, the sphenopalatine ganglion is located behind the nose and only innervates about a third of the head (e.g., the portion located above the sphenopalatine ganglion). Compared to the SCG, the vagus nerve acts more on the brain stem processes while modifying regional blood flows through its connections to trigeminal nerves and spheno-palatine ganglion. The vagus nerve is also thought to have more neural projection for pain processing. The SCG advantageously provides innervation to the musculature of the head and neck, its blood vessels - carotid, vertebral arteries and downstream structures, all of which connect to spinal outflows from the IML, which provides the ability to modify blood flow systematically to deeper brain structures and cortical.
[0050] In several embodiments, the systems described herein are fully implantable. In other embodiments, the electrodes or other nerve effectors are implanted and other components are external. In yet other embodiments, the entire system is not implanted, and the nerve effectors are transcutaneous (over the skin). Nerve effectors may be electrodes or other devices for delivering electrical energy, ultrasound, microwave, etc. to stimulate or otherwise modulate nerves and / or other tissue (such as muscle tissue).
[0051] The technology provided herein, according to several embodiments, provides innovative solutions that use both neuromodulation and Al to help users suffering from migraines. Using machine learningWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaand Al, several embodiments provided herein automatically adjust stimulation parameters to provide personalized therapy, which can be optimized continuously to benefit the user. In several embodiments, machine learning and / or artificial intelligence are used to learn a user’s triggers or auras (as described elsewhere herein) and apply stimulation patterns based on that user’s personalized triggers and auras and / or other data that is sensed automatically and / or input by the user. In several embodiments, algorithms use one or more of the following criteria: feedback from the user or values or changes in biomarkers (e.g., blood flow, pupil diameter, saliva generation, skin perspiration, or otherwise), and then automatically adjust one or more of the following based on the input criteria: (i) stimulation frequency, (ii) pulse width, (iii) intensity, (iv) amplitude, (v) length of stimulation. The data that is used to optimize or otherwise adjust stimulation parameters may be based on sensors, user input (e.g., on a phone app), or both, and thus offer personalized adjustments. Alternatively, stimulation patterns may be adjusted based on population data of a cohort of users or other data.
[0052] Figure 1 is a schematic drawing illustrating the CSC in the right cervical region of the human anatomy. While the right cervical region is shown, the stimulation method disclosed herein may be additionally or alternatively performed on the left cervical region or bilaterally. As shown, the SCG 100 lies on the transverse processes of the C2 vertebra 102 and C3 vertebra 103. The internal carotid artery 114 within the carotid sheath is anterior, and the longus capitis muscle 115 is posterior. The lower end of the SCG 100 is united by a connecting trunk to the top end of the MCG 116. Postganglionic branches are distributed in the internal carotid nerve, which ascends with the internal carotid artery 114 into the carotid canal to enter the cranial cavity, and in lateral, medial, and anterior branches. The postganglionic branches supply vasoconstrictor and sudomotor nerves to the face and neck, dilator pupillae and smooth muscle in the eyelids and orbitalis. The lower end of the MCG 116 is united by a connecting trunk to the top end of the ICG (not shown). An electrode may be introduced in the posterior groove of longus capitis and longus colli muscle groups near a transverse process of a vertebra of the subject. For example, an electrode may be introduced from an inferior location relative to the SCG 100, such as from the region between the C4 vertebra 104 and C5 vertebra 105, or in order to deliver neuromodulation to a location of the CSC between the MCG 116 and the SCG 100, or directly to the SCG 100 itself.
[0053] In accordance with any of the systems described herein, one or more electrodes can be coupled to a lead such that one or more electrodes extend along the SCG 100 and / or at least a portion of the MCG 116. The lead may be placed at the target site via ultrasound guidance due to the proximity of the carotid and other vital arteries. In some embodiments, the lead can be an isodiametric lead such that the lead can be inserted via a needle and followed by an introducer which is visible on ultrasound. The lead can include anchoring elements (e.g., a barb, a tine, a hook, a suture, a balloon, an expanding element, or the like, including combinations thereof), such that when the lead is deployed outside of the introducer, the anchoring elements can engage and allow the lead to remain stable in the anatomy. Since the SCG is located on the anterior surface of the longus colli muscle, the anchoring elements can be positioned to engage (e.g., anchor to) the fascia layer on the longus colli muscle.WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaThe anchoring elements may be positioned to not anchor into the carotid sheath or the CSC directly. The anchoring elements may be positioned at the distal tip of the lead such that the distal end of the lead can be placed at the superior portion of the SCG and the lead can extend inferior along the SCG and longus colli muscle. One or more anchoring elements may also be positioned at a proximal end or portion of the lead. The lead may be positioned to stimulate two ganglia (e.g., the SCG and the MCG), The lead may include a set of 2 to 10 electrodes (e.g., 4 to 6) or any other number of electrodes. The electrode may be grouped together (e.g., without spacing between two sets of electrodes). The electrodes may be directional electrodes (e.g., unidirectional electrodes) (e.g., not circumferential electrodes). The electrodes may be circumferentially spaced to cover between 90 to 360 degrees (e.g., 90 degrees, 120 degrees, 180 degrees, 270 degrees 360 degrees, ranges between such values, and the like), with individual electrodes pointed in each direction. Such an arrangement of electrodes can enable for improved steering of the current. The lead can be highly flexible and soft. The lead may include a small fully capable stimulator implanted with a small rechargeable battery and allow for BLE (Bluetooth) connection (or other wireless connection) with a controller. The stimulator can be placed subcutaneous and can be anchored to the SCM tendon or fascia. In some embodiments, the implanted stimulator may be fully passive and coupled to an external controller via RF coupling, capacitive coupling, etc.
[0054] In some embodiments, a neuromodulation element (e.g., an electrode) can be positioned unilaterally to unilaterally stimulate a left or right CSC. In some embodiments, a neuromodulation element (e.g., an electrode) can be positioned on each of the left and right sides of the subject to stimulate the left CSC and the right CSC bilaterally. In some embodiments, bilateral electrodes may be simultaneously activated to stimulate at the same time. In some embodiments, activation of bilateral electrodes may be alternated such that only one electrode provides stimulation at a time.
[0055] Figures 2 through 10 illustrate example systems and methods for providing neuromodulatory (e.g., stimulation) energy to the SCG for the purpose of treating migraines with aura (MwA) the neuromodulation element may be implanted in a subject at the target stimulation site and stimulation may be applied wirelessly from a remote device, such as a wearable device controlled by the subject. Any of the systems described herein may be used to deliver therapy according to any of the methods described herein. As discussed above, prodromes (e.g., aura), such as, for example, temporary visual disturbances, increased secretions of saliva, and / or increased urination (or increased urge to urinate) may indicate the onset of a migraine in MwA subjects. When the subject begins to experience a prodrome (e.g., in response to the subject experiencing a prodrome), stimulation may be applied to the target site for a specific period of time either continuously or intermittently. Continuous stimulation refers to a time period where stimulation is turned on and left on for the entirety of the stimulation duration. In some embodiments, the stimulation can be intermittent, delivered via an ON-OFF duty cycle. This paradigm involves having stimulation ON at given stimulation parameters (stim intensity, pulse width, frequency, current) interspersed with periods of no stimulation (OFF). This ON-OFF duration might be varied basedWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaon the patient needs and desired outcome (e.g., based on sensor feedback or user input), titrating it to the aura duration and minimizing the effect of CSD. Stimulation may be applied continuously and / or intermittently to the target site for a specific time period (e.g., 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 60 minutes, time periods between such values, less than 3 minutes, less than 5 minutes, less than 10 minutes, less than 15 minutes, less than 30 minutes, less than 60 minutes, and the like). In some embodiments, the stimulation can be delivered for at least a portion of the duration of the aura (e.g., 25% of the duration of the aura, 50% of the duration of the aura, 75% of the duration of the aura, 100% of the duration of the aura, ranges between such values, and the like). Aura may last between 30 to 60 minutes in some subjects. In some embodiments, the stimulation duration can be sufficiently long to ensure stabilization of cerebral blood flow (e.g., at least 20 minutes, at least 30 minutes). The stimulation may be performed at a current of between approximately 1 milliampere (mA) and approximately 10 mA (e.g., at approximately 1 mA, 2 mA, 3 mA, 4 mA, 5 mA, 6 mA, 7 mA, 8 mA, 9 mA, 10 mA, ranges between such values such as 1 mA - 5 mA, 2 mA - 8 mA, 4 mA -10 mA, 1 mA -8 mA, 2 mA - 10 mA, 4 mA -8 mA, or overlapping ranges thereof). The stimulation may be applied at a frequency of between approximately 1 Hertz (Hz) and approximately 100 Hz (e.g., at approximately 1 Hz, 2 Hz, 10 Hz, 15 Hz, 20 Hz, 50 Hz, 75 Hz, 100 Hz, ranges between such values such as 1 Hz - 8 Hz, 2 Hz-12Hz, 10 Hz - 16 Hz, 15 Hz - 30 Hz, 20 Hz - 60 Hz, 50 Hz - 80 Hz, 75 Hz - 90 Hz, less than 5 Hz, less than 10 Hz, or overlapping ranges thereof). The stimulation may be applied with a pulse width of between approximately 50 microseconds (pis) and approximately 2 milliseconds (ms) (e.g., at approximately 50 pis, 500 pis, 600 pis, 700 pis, 800 pis, 900 pis, 1000 pis, 1 ms, 1.5 ms, 1.9 ms, ranges between such values such as 50 pis - 0.3 ms, 100 pis -0.5 ms, 200 pis - 0.7 ms, 300 pis - 1.0 ms, 400 pis - 1.3 ms, 600 pis - 1.6 ms, 800 pis - 2.0 ms, or overlapping ranges thereof). The stimulation may be delivered as continuous stimulation (e.g., not in bursts). The continuous stimulation can include a constant frequency, a constant pulse width, and / or a constant amplitude.
[0056] The stimulation may increase, decrease, and / or stabilize cranial blood flow by preventing the initial cerebral vasoconstriction associated with CSD and aura that causes the reactive cerebral vasodilation and tissue hyper-oxygenation responsible for head pain. The stimulation can inhibit propagation of the CSD wave. The stimulation can cause vasodilation and / or improved blood flow to counteract vasoconstriction caused by CSD. By mitigating the vasoconstriction and associated reactive vasodilation associated with CSD, the stimulation can mitigate or prevent the direct and indirect activation of a trigeminal afferents and subsequent activation of the trigeminal-autonomic reflex to prevent the onset of head pain. Specifically, stimulation can reduce the amount of neurotransmitters being released during the onset activation of pain associated with migraine. CSD causes a release of neurotransmitter in and around the trigeminal afferents nerves that run along the surface of the cerebral vascular. When CSC occurs the neurotransmitter released cause direct activation of trigeminal afferents. When stimulating the CSC, during CSD, the stimulation will stabilize the cerebral vasculature and reduce the amount of neurotransmitters being released as part of the CSD event, which in turn will reduce the amount activation ofWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbatrigeminal afferents and reduce or eliminate the onset activation of the trigeminal-autonomic reflex, which ultimately will reduce or eliminate the pain associated with the aura event. As such, stimulation of the target site(s) serves as a prophylactic treatment for subjects with MwA and autonomic cephalalgias by preventing the process that initiates the pain in migraines from occurring. Stimulation of the cervical sympathetic chain may additionally cause an increase in clearance of one or more of: metabolic waste, the glymphatic system, and meningeal lymphatic vessels. Hemisphere to hemisphere changes in CBF have been linked to preictal prediction of onset of seizures. Accordingly, stimulation of the CSC to cause stabilization of blood flow across cortical hemispheres can also inhibit epilepsy.
[0057] The systems described herein (e.g., the systems 200, 400, 600, 700, 900) generally include a neuromodulation element (e.g., an electrode 202) and a stimulator 204. The systems can also include a controller (also referred to as an activator), which may be onboard with the stimulator or a separate component. The neuromodulation element may comprise one or more of the following means for modulation: a cryogenic element, a radiofrequency element, an ultrasound element (e.g., piezoelectric elements, ultrasound transducers, ultrasound arrays, etc.), a laser element, a thermal delivery element, a chemical delivery element, a microwave element, an electrical element, a pressure element, an acoustic element, a vibratory element, a mechanical stretching element, a light-based element, and / or the like. In systems including an ultrasound element, the ultrasound element can include between 5 and 20 crystals (e.g., 5, 10, 15, 20 crystals, ranges between such values, and the like). In other embodiments, ultrasound element can include between 1 and 50 crystals. The ultrasound element may provide focused ultrasound. The ultrasound element can include a patch or collar externally placed on the patient. The ultrasound element may be activated by an app, remote, or other controller. As discussed below with respect to the various examples, the neuromodulation element may be percutaneously introduced, or partially or fully implanted into the subject at a desired location or target site along the CSC.
[0058] The stimulator of any of the systems described herein can be configured to send a signal to the electrode in response to a user input and may be implanted into the subject, or external to the subject (e.g., in the form of a remote and / or wearable device, for example, a cochlear device). In some embodiments, the therapy may be initiated, stopped, and / or adjusted by the subject, for example, from a remote device, such as a mobile phone, a tablet, a patient controller, a computer, a patch, awearable, or otherwise. The remote device may include the stimulator and / or be a controller in communication with the stimulator. The stimulator can be a pulse generator (e.g., an implanted pulse generator). The stimulator can include and / or be coupled to a power source (e.g., a battery) for powering the stimulator. The stimulator can have an outer diameter of less than 10 mm or less than 20 mm (e.g., 1 mm, 4 mm, 5 mm, 6 mm, 10 mm, 20 mm, ranges between such values, and the like). The stimulator may be sufficiently small to fit through a 10 gauge, 12 gauge, 20 gauge, or smaller needle. The implant can include an anchor (e.g., a barb, a tine, a hook, a suture, a balloon, an expanding element, or the like, including combinations thereof) for anchoring the stimulator to an anatomical feature. In some embodiments, the stimulatorWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbacan be positioned and / or anchored to the back of the skull, the side of the skull, one or more ligaments and / or muscles in the head or neck (e.g., the sternocleidomastoid muscle or tendon), and / or any other anatomical feature.
[0059] The stimulator of any of the systems described herein can include and / or be coupled to a power source (e.g., a battery, such as a lithium polymer ion battery, lithium iodine, lithium manganese dioxide, lithium carbon monofluoride, or any combination thereof). In some embodiments, the power source can be implanted or subcutaneously placed within the subject. In some embodiments, the power source can be positioned external to the subject. The battery may be rechargeable. In some implementations, recharging can be via a wireless charger, including but not limited to an inductive charger. The wireless charger may be placed on the torso of the individual over the location of the stimulator to perform wireless charging. In some implementations, the wireless charger may be secured to a recharge belt and holster to hold the wireless charger in the correct position. The wireless charger, when connected to the controller (wirelessly or in a wired connection), may connect to the stimulator to charge the battery. Alternatively, the battery power source may be a single use.
[0060] The controller (e.g., the activator 406) of any of the systems described herein can be communicatively coupled (e.g., by wired or wireless connection (e.g., via Bluetooth) to the stimulator. The controller may be a remote device, such as, for example, a personal electronic device such as a tablet or smartphone, or any type of computer or device that is capable of activating and / or controlling the stimulator. The controller can be used to control the stimulation parameters of the stimulator. For example, the controller can control the level and timing of stimulation applied by the stimulator. The controller may activate and / or deactivate the stimulator in response to a user input (e.g., from a clinical practitioner or the user themself) such that the neuromodulation element can be selectively powered to control when stimulation energy is applied to the neuromodulation target site. The controller may be used to control (e.g., select, modify, adjust) the stimulation parameters of the stimulation signal generated by the stimulator.
[0061] The controller of any of the systems described herein can include and / or be implemented on one or more processors and one or more memory devices. The one or more memory devices can store processor-executable instructions to perform operations of the controller described herein. The one or more processors can execute the processor-executable instructions corresponding to one or more of the functions of the controller described herein. In some embodiments, the one or more processors may include a microprocessor. In some implementations, the one or more processors may include a clock and a memory device for recording and storing data. The one or more processors may further include hardware and / or software modules for controlling the electrical stimulation generated by the stimulator. The one or more processors may further include hardware and / or software modules for analyzing signals from one or more sensors described elsewhere in the present disclosure. In some implementations, at least some of the processing may be completed on a server, cloud, or other dedicated computing clusters.WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tba
[0062] The one or more processors of any of the systems described herein can process signals and / or data from the stimulator, the neuromodulation element, the one or more of the sensors (e.g., monitoring devices) described herein, and / or the user inputs. The one or more processors may determine stimulation parameters based on received signals and / or data (e.g., via a machine learning algorithm). The one or more processors can send signals and / or instructions to one or more of the stimulator and / or the neuromodulation elements corresponding to and / or based on inputs from a user. The one or more processors can be incommunication (e.g., wired or wireless communication) with and / or coupled to any component of the system (e.g., on-board with the stimulator, in the sensor, in the implantable neuromodulation element, remotely positioned, and the like). The one or more processors may be implanted in the subject and / or external to the subject.
[0063] The stimulator via the neuromodulation element is configured to send electrical signals (e.g., using appropriate energy levels for stimulation and safety of the procedure) to locate the nerves of the SCG 100 for SCG stimulation. Stimulation of the SCG 100 may include stimulation of the cell bodies and / or axons passing through the SCG 100. It is to be understood that any reference herein to the stimulation of the SCG also encompasses stimulation of the conductive muscle tissue surrounding the SCG, nerve fibers branching off the SCG, and vice versa. The stimulator may be an external, internal (e.g., the stimulator can be externally powered via inductive coupling), or have components split between both internal and external. The stimulator may comprise wired or wireless communication (e.g., configured to communicate with the neuromodulation element, a hospital system, a computer, a handheld device such as a phone or tablet, etc.). If the neuromodulation element comprises electrodes, the stimulator can generate an electrical signal configured for SCG stimulation. Low stimulation parameters (e.g., voltage, pulse width, frequency, amplitude, duration, etc.) may be sufficient for inducing a sympathetic response (e.g., increased blood flow, pupillary response) in a subject, and avoid inadvertently stimulating nerves or muscles other than the target site. In some embodiments, low stimulation parameters can include a frequency of equal to or less than 10 Hz and a duration of equal to or less than 30 minutes (and values and ranges below such parameters elsewhere provided herein). Although certain systems and methods described herein specifically target the SCG, the systems and methods may be generally applied to the cervical sympathetic chain, including locations between the MCG and the SCG.
[0064] In some examples, the system may additionally include one or more monitoring devices (e.g., imaging modality 508 or sensor). In some embodiments, the one or more monitoring devices may be used to track and detect changes in the cerebral effects of the stimulation in real-time. In some embodiments, the one or more monitoring devices may be used to detect a prodrome indicating onset of cephalalgia. This may be achieved, for example, by observing changes in one or more physical biomarkers such as, for example, blood flow, pupil diameter, saliva generation, skin perspiration, etc. Depending on the biomarker(s) being monitored, the one or more monitoring devices may include, for example, a blood flow monitoring device (e.g., doppler ultrasound, pulse oximeters, blood pressure cuffs, blood vessel cuffs, wearable devices with photoplethysmography (PPG)WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbasensors, etc.), a cerebral imaging modality such as near infrared spectroscopy (NIRS), a pupillometry device, a device capable of monitoring saliva generation (e.g., smart mouthguards, biosensors, smart pacifiers, etc.), or any other device capable of monitoring and / or detecting changes in physical biomarkers that are affected by the stimulation in real time. NIRS can be used to sense cortical or superficial blood flow. Sympathetic nervous system activity can be sensed through skin impedance measurements, among other techniques. For detecting a prodrome, the monitoring device can detect a change in a biomarker associated with a prodrome (e.g., aura) indicating onset of cephalalgia. For example, the monitoring device may include a device for monitoring saliva generation or a sensor for detecting skin perspiration. In some embodiments, the stimulator can send a signal to the electrode to electrically stimulate the cervical sympathetic chain in response to the monitoring device detecting the change in the biomarker associated with a prodrome. In some embodiments, the system may not include any sensors (e.g., an open loop system). In some cases, the system may automatically determine the optimal stimulation parameters based on the measured biomarkers using machine learning and / or artificial intelligence algorithms. The one or more machine learning and / or artificial intelligence models may be trained on raw and / or processed signals measured by the stimulator, sensors, and systems disclosed herein. In some instances, the one or more machine learning and / or artificial intelligence models may alternatively, or in addition to, be trained on user feedback regarding whether or not the stimulation parameters prevented migraine pain, and / or whether such parameters caused any discomfort.
[0065] Figure 2 is a schematic diagram of an example system 200 for modulating nerves as described above, which may be suitable for an at-home setting. The system may comprise a neuromodulation element (e.g., an electrode 202) implanted at a target site of the subject 150 (e.g., as described above) and an external stimulator 204. The external stimulator 204 may be configured to power and / or send a control signal to the electrode 202 in order to provide neuromodulatory (e.g., stimulation) energy to the target site. The external stimulator 204 may be wired or wirelessly coupled with the electrode (e.g., via RF pulse, capacitive coupling, inductive coupling, or the like). The system 200 can include a controller as described above (e.g., an activator 406) for activating and / or controlling the stimulator 204. The system 200 (and any of the systems described herein) can include and / or be implemented using one or more processors. In some embodiments, the electrode 202 can be coupled to a carotid stent and oriented into the sympathetic chain.
[0066] Figure 3 is a flowchart of a method 300 corresponding to an example of the above-described method of treating a subject for migraines using the example system 200 of Figure 2. First, at block 302, the electrode 202 (or other neuromodulation element) is positioned (e.g., implanted) at the target site of the subject 150. At block 304, a subject 150 begins to experience prodromes indicating the onset of migraine with aura. At block 306, when a subject 150 begins to experience prodromes indicating the onset of migraine with aura, the subject 150 may activate the external stimulator 204 (e.g., via a controller built in with or remote from the stimulator) to power the electrode 202. At block 308, stimulation is applied to the target site via the electrode 202. ExamplesWIPRef: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaof prodromes may include, but are not limited to, temporary visual disturbances, increased secretions of saliva, and increased urination.
[0067] Figure 4 is a schematic diagram of another example at-home system 400 for modulating nerves as described above, where both a stimulator 204 and a neuromodulation element (e.g., electrode 202) are fully implanted in a subject 150. The stimulator 204 can be controlled by an external activator 406 (also referred to as a controller as described above), for example to activate power to the stimulator 204 and provide neuromodulatory (e.g., stimulation) energy to the target site via the electrode 202. The stimulator 204 can include and / or be coupled to a receiver (or a transceiver) for communicating (e.g., wirelessly communicating with the activator). For example, the electrode 202, the stimulator 204 (e.g., a pulse generator), a receiver, and / or a power source (e.g., a battery) can be fully implanted in the subject. The stimulator 204 may be wired or wirelessly coupled with the electrode (e.g., via RF pulse, capacitive coupling, inductive coupling, or the like).
[0068] Figure 5 is a flowchart of a method 500 corresponding to an example of the above-described method of treating a subject for migraines using the example system 400 of Figure 4. First, at block 502, the electrode 202 (or other neuromodulation element) is positioned (e.g., implanted) at a target site in a subject 150. At block 504, the stimulator 204 is also implanted in the subject 150. At block 506, the subject 150 begins to experience prodromes indicating the onset of a migraine with aura. At block 509, when a subject 150 begins to experience prodromes indicating the onset of a migraine with aura, the subject 150 may use an external activator 406 to instruct the stimulator 204 to power the electrode 202. At block 510, the stimulator 204 sends a signal to the electrode 202. At block 512, stimulation is applied at the target site via the electrode 202.
[0069] Figure 6 is a schematic diagram of an example system 600 corresponding to the abovedescribed clinical system for modulating nerves. The system 600 may include a neuromodulation element (e.g., an electrode 202) and an external stimulator 204 configured to send power to the electrode 202. The system 600 can include a controller as described above (e.g., an activator 406) for activating and / or controlling the stimulator 204. The electrode 202 can be placed (e.g., percutaneously introduced) to the target site of the subject 150 by a clinician. In some examples, an imaging modality 508 such as an ultrasound device may be used to aid the clinician in placing the electrode 202 at the target site.
[0070] Figure 7 is a schematic diagram of another example system 700 corresponding to the above-described clinical system for modulating nerves. The system 700 may include an electrode 202 disposed on a tip of a needle 710 which is in powered communication with an external stimulator 204. The system 700 can include a controller as described above (e.g., an activator 406) for activating and / or controlling the stimulator 204. The electrode 202 may be percutaneously introduced to the target site in the subject 150 by the clinician using the needle 710. In some examples, an imaging modality 508, such as an ultrasound device, may be used to aid the clinician in placing the electrode 202 at the target site.WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tba
[0071] Figure 8 is a flowchart of an example of a method 800 corresponding to the above-described method of treating a subject for migraines using the example clinical systems 600, 700 of either Figure 6 or Figure 7. As discussed above, at block 802, the clinician may first position (e.g., percutaneously) the electrode 202 at the target site. In some cases, an imaging modality 508 (e.g., an ultrasound device) may be used to help accurately position the electrode 202 at the target site. For example, a subject 150 may be placed in the supine position with the neck in slight extension. A high-frequency linear transducer (e.g., an ultrasound transducer) may be placed at a particular vertebral level (e.g., the level of the C6 vertebra) to allow for cross-sectional visualization of anatomic structures, including the transverse process and anterior tubercle of the particular vertebra (e.g., C6 vertebra), the muscle layers under the CSC that make up the carotid complex, the longus colli muscle and prevertebral fascia, the carotid artery, and the thyroid gland. In some cases, a pre-scan may optionally be performed on the subject 150 to aid in planning the path of needle insertion. For example, the planned path of needle insertion may be in between the carotid artery and the trachea to avoid inadvertently contacting and / or puncturing the esophagus and the inferior thyroidal artery. In some examples, the needle 710 may be inserted laterally relative to the carotid artery, while the tip of the needle 710 is simultaneously or subsequently directed towards the prevertebral fascia between the carotid artery and the tip of the anterior tubercle of the particular vertebra (e.g., C6 vertebra). This exemplary needle path may be desirable to avoid hitting the cervical nerve root. Additionally, in some examples, the internal jugular vein may be visualized by decreasing the pressure of the ultrasound transducer, to allow the clinician to direct the needle 710 away from the internal jugular vein towards the target site. In some embodiments, once the needle 710 is placed at the target site, a lead having one or more electrodes 202 designed to apply the modes of stimulation discussed herein, may be inserted (e.g., percutaneously) into the subject 150 and tracked along the longus colli muscle in a superior direction until the electrodes 202 reach the target location. Once the electrodes 202 are delivered to the target site, they may be inserted or implanted at the target via various methods. For example, the lead may include a stylet that allows for the lead and / or electrodes 202 to be pushed and curved into the correct location by a needle 710. When using an ultrasound technique, the electrode 202 can be introduced medially or laterally. Because the CSC sits on the longus colli muscle, lateral placement may advantageously avoid any injury to the carotid. In some embodiments, the electrode 202 may be intravascularly placed (e.g., through the internal carotid artery) for intravascular stimulation.
[0072] In an alternate example, the needle 710 may be coupled to a sheath while both the needle 710 and sheath are delivered (e.g., percutaneously) to the target site. Once positioned at the target site, the needle 710 may be removed from the subject 150 and decoupled from the sheath such that the sheath remains at the target site after the needle 710 is removed. The sheath may then serve as a channel through which one or more electrodes 202 can be navigated through and advanced towards the target site.
[0073] In yet another example, the one or more electrodes 202 may be delivered to the target site via an over-the-wire approach. In such examples, a blunt tip wire may be introduced (e.g., percutaneously) intoWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbathe subject 150 and used to create a path towards the target site. Once the wire is correctly placed, the lead may be inserted over the wire into the target location, after which point the wire may be removed to allow the lead to be connected to the external stimulator 204.
[0074] At block 804, once the one or more electrodes 202 are positioned at the target site, an external stimulator 204 may then be used to activate the electrode 202. At block 806, the electrode 202 can deliver neuromodulatory (e.g., stimulation) energy to the target site. At block 808, the clinician may then monitor a change in one or more physiological biomarkers of the subject 150 to confirm correct placement of the electrode 202 at the target site and assess the need for further neuromodulation. If no changes in biomarkers are observed, the position of the electrode 202 may be re-adjusted using further imaging to properly target the target stimulation site, and stimulation may be re-applied.
[0075] Figure 9 is a schematic diagram of an example system 900 for modulating nerves that is fully external to a subject 150 as described above. As shown in Figure 9, the system 900 can include an electrode 202 and a stimulator 204 that are both positioned external to the subject 150. The system 900 can include a controller as described above (e.g., an activator 406) for activating and / or controlling the stimulator 204.
[0076] Figure 10 is a flowchart of an example method 1000 of treating a subject for migraines using the example system 900 of Figure 9. First, at block 1002, an electrode 202 (e.g., an electrode contact) may be positioned on a subject’s skin. The electrode 202 may be positioned on the subject’s head, neck, or face. At block 1004, the electrode 202 can then be activated by a stimulator 204 to provide neuromodulatory (e.g., stimulation) energy to the subject 150. At block 1006, stimulation can be applied to the target site via the electrode 202. At block 1008, the clinician may then monitor a change in one or more physiological biomarkers of the subject 150 to confirm correct placement of the electrode at the target site and assess the need for further neuromodulation. If no changes in biomarkers are observed, the position of the electrode may be re-adjusted using further imaging to properly target the target stimulation site, and stimulation may be re-applied.
[0077] As used and described herein, neuromodulation may refer to modulation of one or more types of nervous tissue (e.g., nerves (e.g., neuronal axons) and branches therefrom (e.g., rami), ganglia (e.g., neuronal cell bodies), etc.), may include one or more modulation types (e.g., stimulation, ablation, denervation, nerve blocking, and / or the like), and may be performed via one or more modulation modalities (e.g., cryogenic, radiofrequency, ultrasound, laser, thermal, chemical, electromagnetic radiation (e.g., microwave radiation), electrical, pressure, acoustic, vibratory, mechanical stretching, and / or the like). While the systems and methods provided herein may be described in the context of a specific nervous tissue type, modulation type, or modulation modality, it is to be understood that any of systems and methods provided herein can be used to treat any tissue type (e.g., any nervous tissue or non-nervous tissue type), according to any modulation type, and via any modulation modality.WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tba
[0078] In several embodiments, the neuromodulation therapies described herein can be used to replace pharmacological (drug) therapies. In other embodiments, however, drug therapies may be used in combination with the neuromodulation therapies described herein, but with reduced frequency or dose, thus reducing undesired side effects. For example, a certain drug (or drug combination) may be administered for a shorter overall duration, fewer times per day / week / month, and / or at a lower dose when combined with the neuromodulation described herein. In addition to reducing undesired pharmacological side effects, this may also reduce addiction or dependence. The neuromodulation described herein may also be used to taper or otherwise wean subjects off of pain and other medications.
[0079] Certain experiments are described with respect to application of medicaments, for example to induce certain physiological conditions before, during, and / or after stimulation. The devices and methods described herein can be used without medicaments (e.g., without medicaments inducing certain physiological conditions). Anesthetics and other medicaments that enable electrode contact placement, for example, may be used. Substances released by the subject in response to stimulation (e.g., calcitonin gene-related peptide (CGRP)) would not be considered a medicament.
[0080] The foregoing description and examples are set forth merely to illustrate the inventive concepts and are not intended as being limiting. Each of the disclosed embodiments and examples of the present disclosure may be considered individually or in combination with other embodiments, examples, and variations of the disclosure. In addition, unless otherwise specified, none of the steps of the methods of the present disclosure are confined to any particular order of performance. Modifications of the disclosed examples incorporating the spirit and substance of the disclosure and such modifications are within the scope of the present disclosure. Furthermore, all references cited herein are incorporated by reference in their entirety. Headings used herein are for organizational purposes only and should not be used to unduly limit claim scope or embodiments.
[0081] While the methods and devices described herein may be susceptible to various modifications and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular devices or methods disclosed, but, to the contrary, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the various examples described and the appended claims. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with an example can be used in all other examples set forth herein. Any methods disclosed herein need not be performed in the order recited. Depending on the example, one or more acts, events, or functions of any of the algorithms, methods, or processes described herein can be performed in a different sequence, can be added, merged, or left out altogether (e.g., not all described acts or events are necessary for the practice of the algorithm). Algorithms, modules, blocks, steps, boxes, elements, features, etc. may be stored in machine-readable memory. In some examples, acts or events can be performed concurrently, e.g., throughWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbamulti-threaded processing, interrupt processing, or multiple processors or processor cores or on other parallel architectures, rather than sequentially. Further, no element, feature, block, box, or step, or group of elements, features, blocks, boxes, or steps, are necessary or indispensable to each example. Additionally, all possible combinations, sub-combinations, and rearrangements of systems, methods, features, elements, modules, blocks, boxes, and so forth are within the scope of this disclosure. The use of sequential, or time-ordered language, such as “then,” “next,” “after,” “subsequently,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to facilitate the flow of the text and is not intended to limit the sequence of operations performed. Thus, some examples may be performed using the sequence of operations described herein, while other examples may be performed following a different sequence of operations.
[0082] The various illustrative logical blocks, boxes, modules, processes, methods, and algorithms described in connection with the examples disclosed herein can be implemented as electronic hardware, computer software, or combinations of both. To clearly illustrate this interchangeability of hardware and software, various illustrative components, blocks, modules, operations, and steps have been described above generally in terms of their functionality. Whether such functionality is implemented as hardware or software depends upon the particular application and design constraints imposed on the overall system. The described functionality can be implemented in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the disclosure.
[0083] The various illustrative logical blocks and modules described in connection with the examples disclosed herein can be implemented or performed by a machine, such as a general purpose processor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. A general purpose processor can be a microprocessor, but in the alternative, the processor can be a controller, microcontroller, or state machine, combinations of the same, or the like. A processor can also be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration.
[0084] The blocks, operations, or steps of a method, process, or algorithm described in connection with the examples disclosed herein can be embodied directly in hardware, in a software module executed by a processor, or in a combination of the two. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, an optical disc (e.g., CD-ROM or DVD), or any other form of volatile or non-volatile computer-readable storage medium known in the art. A storage medium can be coupled to the processor such that the processor can read information from, and write information to, the storage medium. In the alternative, the storage medium can be integral to the processor. TheWIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaprocessor and the storage medium can reside in an ASIC. The ASIC can reside in a user terminal. In the alternative, the processor and the storage medium can reside as discrete components in a user terminal.
[0085] Conditional language used herein, such as, among others, “can,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that some examples include, while other examples do not include, certain features, elements, and / or states. Thus, such conditional language is not generally intended to imply that features, elements, blocks, and / or states are in any way required for one or more examples or that one or more examples necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and / or states are included or are to be performed in any particular example.
[0086] The methods disclosed herein may include certain actions taken by a practitioner; however, the methods can also include any third-party instruction of those actions, either expressly or by implication. For example, actions such as “stimulating a nerve” include “instructing stimulation of a nerve.”
[0087] The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as “up to,” “at least,” “greater than,” “less than,” “between,” and the like includes the number recited. Numbers preceded by a term such as “about” or “approximately” include the recited numbers and should be interpreted based on the circumstances (e.g., as accurate as reasonably possible under the circumstances, for example ±5%). For example, “about 1 mm” includes “1 mm.” Phrases preceded by a term such as “substantially” include the recited phrase and should be interpreted based on the circumstances (e.g., as much as reasonably possible under the circumstances). For example, “substantially parallel” includes “parallel.” Unless stated otherwise, all measurements are at standard conditions including temperature and pressure. The phrase “at least one of’ is intended to require at least one item from the subsequent listing, not one type of each item in the subsequent listing. For example, “at least one of A, B, and C” can include A, B, C, A and B, A and C, B and C, or A, B, and C. Where systems or methods “comprise” or “include” certain features or steps, such devices or methods may also “consist” or “consist essentially of’ such features or steps if identified as such in the claims. Thus, disclosure herein of systems and methods that comprise the stimulation of the cervical sympathetic chain (which may include other nerves / tissue), also provides support for systems and methods that consist or consist essentially of the stimulation of the cervical sympathetic chain. As another example, disclosure herein of systems and methods that comprise one electrode (which may include more than one electrode) also provides support for systems and methods that consist or consist essentially of one electrode.
[0088] Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure pertains. As used herein, the singular forms “a,” “an,” and “the” can also include the plural forms, unless the context clearly indicates otherwise. As used herein, the terms “comprises” and / or “comprising,” can specify the presence of stated features, steps, operations, elements, components, and / or groups, but do not preclude the presence or addition of one orWIPRef: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbamore other features, steps, operations, elements, components, and / or groups. As used herein, the term “and / or” can include any and all combinations of one or more of the associated listed items. As used herein, the terms “first,” “second,” etc. should not limit the elements being described by these terms. These terms are only used to distinguish one element from another. Thus, a “first” element discussed below could also be termed a “second” element without departing from the teachings of the present disclosure. The sequence of operations (or acts / steps) is not limited to the order presented in the claims or figures unless specifically indicated otherwise. As used herein, the term “sympathetic nervous system” can refer to a portion of the autonomic nervous system that activates the “Fight or Flight” response (generally accelerating heart rate, dilating pupils, dilating bronchioles, inhibiting digestion, constricting blood vessels, increasing cardiac output, and raising blood pressure, etc.), which prepares the body for intense physical activity. As used herein, the term “electrical signal” can refer to a time-varying voltage or current. As an example, the electrical signal can be represented by a waveform (a graphical representation of changes in current or voltage over time). As used herein, the term “electrode contact” can refer to a material acting as a conductor through which electricity enters or leaves. At least a portion of the material can be a biocompatible material. As used herein, the terms “subject” and “patient” can be used interchangeably and refer to any warmblooded organism including, but not limited to, a human being and other mammals.
Claims
WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaWHAT IS CLAIMED IS:
1. A system for electrically stimulating a cervical sympathetic chain in a subject to treat cortical spreading depression, the system comprising:an implantable electrode configured to be positioned in electrical communication with the cervical sympathetic chain of the subject;a stimulator configured to send a stimulation signal to the implantable electrode to electrically stimulate the cervical sympathetic chain; anda processor, the processor configured to:receive an input from the subject; andin response to receiving the input from the subject, send instructions to the stimulator to send the stimulation signal to the implantable electrode,wherein the implantable electrode, upon receiving the stimulation signal, stimulates the cervical sympathetic chain to reduce cortical spreading depression.
2. The system of claim 1, wherein the stimulation signal comprises a frequency of less than or equal to 10 Hz.
3. The system of claim 1 or 2, wherein the stimulation signal comprises a duration between 5 minutes and 60 minutes.
4. The system of any one of claims 1 to 3, wherein the stimulator comprises an implantable anchor configured to be anchored to a muscle of the subject.
5. The system of any one of claims 1 to 4, wherein the implantable electrode is configured to be positioned in electrical communication with a superior cervical ganglion.
6. A system for electrically stimulating a cervical sympathetic chain in a subject to treat cortical spreading depression, the system comprising:an implantable electrode configured to be positioned in electrical communication with the cervical sympathetic chain of the subject;a stimulator configured to send a stimulation signal to the implantable electrode to electrically stimulate the cervical sympathetic chain,the stimulator comprising an anchor configured to be anchored to a sternocleidomastoid muscle or tendon of the subject; anda processor, the processor configured to:receive an input from a user; andin response to receiving the input from the user, send instructions to the stimulator to send the stimulation signal to the implantable electrode,-26-WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbawherein the stimulation signal comprises a frequency of less than or equal to 10 Hz at a duration between 5 minutes and 60 minutes.
7. The system of any one of claims 1 to 6, further comprising a second implantable electrode configured to be positioned in electrical communication with a middle cervical ganglion.
8. The system of any one of claims 1 to 7, further comprising a monitoring device configured to monitor one or more biomarkers of the subject, wherein the stimulator is configured to send the stimulation signal to the implantable electrode based on the one or more biomarkers detected.
9. The system of claim 8, wherein the one or more biomarkers comprise one or more of cranial blood flow, pupil size, and saliva generation.
10. The system of claim 8, wherein the monitoring device comprises an imaging modality configured to monitor one or more cranial biomarkers of the subject, wherein the imaging modality comprises near infrared spectroscopy (NIRS).
11. The system of any one of claims 1 to 10, wherein a frequency and / or a duration of the stimulation signal is determined using artificial intelligence.
12. The system of any one of claims 1 to 11, wherein the electrical stimulation of the cervical sympathetic chain causes an increase in clearance of one or more of metabolic waste, a glymphatic system of the subject, and meningeal lymphatic vessels of a subject.
13. The system of any one of claims 1 to 12, wherein the electrical stimulation of the cervical sympathetic chain is configured to cause cerebral vasodilation to mitigate the cortical spreading depression prior to onset of pain associated with the cortical spreading depression.
14. The system of any one of claims 1 to 13, wherein the implantable electrode is configured to be positioned to stimulate the cervical sympathetic chain without stimulating a sphenopalatine ganglion, spinal cord, or vagus nerve.
15. A method for treating cortical spreading depression in a subject, the method comprising:positioning an implantable electrode in electrical communication with a cervical sympathetic chain of the subject;in response to the subject experiencing a prodrome indicating onset of cephalalgia, sending, via a stimulator, a stimulation signal to the implantable electrode to electrically stimulate the cervical sympathetic chain; andelectrically stimulating the cervical sympathetic chain via the implantable electrode to cause cerebral vasodilation to mitigate cortical spreading depression prior to onset of cephalalgia associated with cortical spreading depression.
16. A method for treating cortical spreading depression in a subject, the method comprising:WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbapositioning an implantable electrode in electrical communication with a cervical sympathetic chain of the subject;in response to the subject experiencing aura indicating onset of a migraine with aura, sending, via a stimulator, a stimulation signal to the implantable electrode to electrically stimulate the cervical sympathetic chain; andelectrically stimulating the cervical sympathetic chain via the implantable electrode to cause stabilization of cerebral blood flow to mitigate cortical spreading depression without treating pain associated with the migraine.
17. A method for treating cortical spreading depression in a subject, the method comprising:positioning an implantable electrode in electrical communication with a superior cervical ganglion of the subject;in response to the subject experiencing aura indicating onset of a migraine with aura, sending, via a stimulator, a stimulation signal to the implantable electrode to electrically stimulate the superior cervical ganglion; andelectrically stimulating the superior cervical ganglion via the implantable electrode to stabilize cerebral blood flow,wherein stabilizing cerebral blood flow mitigates activation of a trigeminal autonomic reflex to prevent onset of head pain.
18. The method of any one of Claims 15 to 17, wherein the prodrome or aura comprises visual disturbances, increased secretions of saliva, and / or increased urge to urinate.
19. The method of any one of Claims 15 to 18, wherein the electrical stimulation is delivered at a frequency of less than or equal to 10 Hz.
20. The method of any one of Claims 15 to 19, wherein the electrical stimulation is delivered for a duration between 5 minutes and 60 minutes.
21. The method of any one of Claims 15 to 20, wherein the electrical stimulation of the cervical sympathetic chain causes an increase in clearance of one or more of metabolic waste, a glymphatic system of the subject, and meningeal lymphatic vessels of a subject.
22. The method of any one of Claims 15 to 21, further comprising anchoring the stimulator to a sternocleidomastoid muscle or tendon of the subject.
23. The method of any one of Claims 15 to 22, wherein the implantable electrode is positioned to stimulate the cervical sympathetic chain without stimulating a spinal cord, vagus nerve, or sphenopalatine ganglion.
24. A system for electrically stimulating a cervical sympathetic chain in a subject to prophylactical ly treat cephalalgia, the system comprising:WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbaan implantable electrode configured to be delivered into electrical communication with the cervical sympathetic chain;a monitoring device configured to detect a change in a biomarker of the subject associated with a prodrome indicating onset of cephalalgia; anda stimulator configured to send a signal to the implantable electrode to electrically stimulate the cervical sympathetic chain in response to the monitoring device detecting the change in the biomarker.
25. The system of Claim 24, wherein the biomarker includes one or more of skin perspiration and saliva generation.
26. The system of Claim 24 or 25, wherein the stimulator is wearable.
27. A method for modulating cranial blood flow in a subject, the method comprising:positioning an implantable electrode in electrical communication with a cervical sympathetic chain of the subject;activating an external stimulator configured to send a signal to the implantable electrode; and electrically stimulating the cervical sympathetic chain via the implantable electrode in response to the signal.
28. The method of Claim 27, wherein the stimulation is applied to treat symptoms of migraine with aura.
29. The method of Claim 27 or 28, wherein the stimulation is initiated by the subject in response to a prodrome, wherein the prodrome comprises any one of temporary visual disturbances, increased secretions of saliva, and / or increased urination.
30. The method of any one of Claims 27 to 29, wherein electrically stimulating the cervical sympathetic chain increases, decreases, or stabilizes cranial blood flow.
31. The method of any one of Claims 27 to 30, wherein electrically stimulating the cervical sympathetic chain increases in clearance ofone or more of metabolic waste, a glymphatic system of the subject, and meningeal lymphatic vessels of a subject.
32. The method of any one of Claims 27 to 31 , wherein activating the external stimulator comprises the subject inputting an instruction on a wearable device.
33. The method of any one of Claims 27 to 32, further comprising locating a target site on the cervical sympathetic chain of the subject, wherein the implantable electrode is positioned at the target site.
34. The method of Claim 33, wherein the target site is located at or proximate to a superior cervical ganglion of the subject.
35. The method of Claim 33, wherein the target site is located at a region of the cervical sympathetic chain between a middle cervical ganglion and a superior cervical ganglion of the subject.
36. A method for electrically stimulating a cervical sympathetic chain in a subject, the method comprising:-29-WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tbapositioning an electrode in electrical communication with a cervical sympathetic chain of the subject;activating a stimulator to send a signal to the electrode in response to a clinician input to send the signal to the electrode to electrically stimulate the cervical sympathetic chain; andelectrically stimulating the cervical sympathetic chain via the electrode.
37. The method of Claim 36, wherein the positioning comprises percutaneously inserting a needle into a target site of the cervical sympathetic chain, wherein the electrode is disposed on a distal tip of the needle.
38. The method of Claim 37, wherein the target site is located at or near a superior cervical ganglion of the subject.
39. The method of Claim 37, wherein the target site is located at a region of the cervical sympathetic chain between a middle cervical ganglion and a superior cervical ganglion of the subject.
40. The method of any one of Claims 36 to 39, wherein electrically stimulating the cervical sympathetic chain stabilizes cranial blood flow.
41. The method of any one of Claims 36 to 40, wherein electrically stimulating the cervical sympathetic chain increases clearance of one or more of metabolic waste, a glymphatic system of the subject, and meningeal lymphatic vessels of a subject.
42. The method of any one of Claims 36 to 41, wherein the clinician input is made in response to an observed change in cranial blood flow.
43. A method of modulating cranial blood flow in a subject, the method comprising:locating a target stimulation site on a cervical sympathetic chain of the subject; positioning an electrode at the target stimulation site;activating a stimulator to send a signal to the electrode;detecting a change in a physiological parameter or condition of the subject; and electrically stimulating the cervical sympathetic chain via the electrode based on the detected physiological parameter or condition.
44. The method of Claim 43, wherein positioning the electrode at the target stimulation site comprises percutaneously introducing a needle into vasculature of the subject, wherein the electrode is located at a distal tip of the needle.
45. The method of Claims 43 or 44, wherein positioning the electrode at the target stimulation site comprises percutaneously introducing a needle in a posterior groove of longus capitis and longus colli muscle groups near a transverse process of a vertebra of the subject, wherein the electrode is located at a distal tip of the needle.
46. The method of any one of Claims 43 to 45, wherein detecting a change in a physiological parameter of the subject comprises detecting a change in cranial blood flow.-30-WIPRef.: 50000.KMO.P110PC May 15, 2026 Official Ref. : tba47. The method of any one of Claims 43 to 46, wherein detecting a change in a physiological parameter of the subject comprises detecting skin sympathetic nerve activity.
48. The method of any one of Claims 43 to 47, wherein the target stimulation site is located at or near a superior cervical ganglion of a subject.
49. The method of any one of Claims 43 to 48, wherein the target stimulation site is between a middle cervical ganglion and a superior cervical ganglion of the subject.
50. The method of any one of Claims 43 to 49, wherein locating a target stimulation site is achieved via ultrasound imaging.
51. The method of any one of Claims 43 to 50, wherein detecting a change in a physiological parameter or condition of the subject is achieved via near infrared spectroscopy (NIRS).
52. The use of a system and method of any of the preceding claims for the prevention and / or treatment of one or more of migraine, headache disorders, stroke, and brain injury.
53. Use of the system of any one of any of the preceding claims for the treatment of cortical spreading depression without treating pain associated with a migraine.
54. Use of the system of any one of any of the preceding claims for the stimulation of the cervical sympathetic chain without stimulating the spinal cord, lumbar sympathetic chain, inferior cervical ganglia, postganglionic branches or connections of the SCG, the vagus nerve, and / or the sphenopalatine ganglion.
55. A system and method of any of the preceding claims, wherein artificial intelligence and / or machine learning are used to optimize stimulation patterns.
56. A system and method of any of the preceding claims, wherein said systems and methods provide synergistic combination therapies with drugs and other interventions.
57. A system and method of any of the preceding claims, wherein said systems and methods provide open-loop feedback, closed-loop-feedback, or both, and neurostimulation parameters are provided and / or adjusted based on such feedback.-31-
